Please use this identifier to cite or link to this item:
|標題:||Antiviral therapy targeting viral polymerase||作者:||Tsai, C.H.
|關鍵字:||hepatitis-c virus;herpes-simplex-virus;hiv-1 reverse-transcriptase;dependent rna-polymerase;cytomegalovirus dna-polymerase;varicella-zoster-virus;decreased replication capacity;nonstructural 5a;protein;double-stranded dna;p-gene-product||Project:||Current Pharmaceutical Design||期刊/報告no：:||Current Pharmaceutical Design, Volume 12, Issue 11, Page(s) 1339-1355.||摘要:||
Viral DNA and RNA polymerases are enzymes, which are responsible for copying the genetic materials of viruses and are therefore central components in the life cycles of viruses. The polymerases are essentially required for the replication of viruses. The reverse transcriptase (RT) of the retroviruses and the hepadnaviruses is the sole viral enzyme required for the synthesis of DNA from viral RNA. Viral polymerases are therefore an extremely favorable target for the development of antiviral therapy. The success of anti-HIV-1 therapy using inhibitors specifically targeting HIV RT suggests that other viral polymerases can be the valid molecular targets for the design of antiviral drugs. Intensive structural and functional studies of viral polymerases have been conducted and have opened new avenues for the development of more effective antiviral therapy. This review summarizes the insights gained from recent structural and functional studies of antiviral agents, which target viral polymearses. The primary focus will be on hepatitis C virus (HCV), herpesviruses, HIV, hepatitis B virus (HBV) and influenza virus.
|Appears in Collections:||生物科技學研究所|
Show full item record
TAIR Related Article
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.